JPMorgan: Is Gold Priced at $4,600 Really Expensive?

JPMorgan pointed out that, according to the traditional model (fair value of $1,000-$1,900), gold is significantly overvalued, but this does not mean it is "wrong"—the high premium reflects a rational pricing of geopolitical risks, damaged U.S. dollar credibility, and the failure of the 60/40 portfolio. The real drivers of the rally—the "century rebalancing" of Western pension funds into gold and stagflation trades—have yet to kick in, and $4,600 may be a worthwhile "insurance premium" to pay.

wallstreetcnMay 7 13:48

Hebang Biotechnology (603077): Chemicals Sector Reverses Difficulties, Mining Initiates Second Growth Curve!

Event: ① The company released its 2025 annual report and the first quarter report of 2026. In 2025, the company achieved operating revenue of 7.188 billion yuan, a year-on-year decrease of 15.91%; net profit attributable to shareholders was -536 million yuan, a year-on-year decrease of 1.

SDIC SecuritiesApr 27 00:00

Hebang Biochemical (603077.SH): Technical transformation of certain product production lines

Gelonghui, April 21st - Hefang Biochemical (603077.SH) announced that, affected by intensified market competition for related products, the company plans to upgrade and renovate certain production lines to enhance product competitiveness. The details are as follows: Due to the long operational period of the company's combined alkali production facilities, the startup time for Combined Alkali Plant Two was in 2003, while the startup time for Combined Alkali Plant One was in 2009. All the aforementioned equipment has entered an aging state, resulting in reduced operational efficiency and higher production costs. To improve the market competitiveness of its combined alkali products, the company intends to carry out technological upgrades on the combined alkali production facilities by enhancing

Gelonghui FinanceApr 21 15:36

Hebang Bio-Science's stock fell 7% following a reported net loss of 5.36 billion yuan in 2025, reversing from a profit in the previous year.

Gelonghui reported on April 21 that Hebang Bio (603077.SH) fell by 7.06% to RMB 3.03 per share, with a market capitalization of RMB 26.76 billion. According to Hebang Bio's 2025 annual report, the company achieved a total revenue of RMB 7.188 billion for the year, representing a year-on-year decrease of 15.91%. It also reported a net loss attributable to shareholders of RMB 536 million, compared to a net profit of RMB 31.4647 million in the previous year. (Gelonghui)

Gelonghui FinanceApr 21 15:01

Hebang Biotechnology reported revenue of 7.188 billion yuan in 2025, a year-on-year decrease of 15.91%, with a net loss attributable to shareholders of 536 million yuan.

Hebang Biotech reported revenue of 7.188 billion yuan in 2025, a year-on-year decrease of 15.91%, with a net loss attributable to shareholders of 536 million yuan.

lanjinger.comApr 21 10:54

Sichuan Hebang Biotechnology: Hebang Biotechnology 2026 Q1 Report

SZSIApr 21 00:00 · Announcements